ZNTL
Zentalis Pharmaceuticals, Inc.
Next earnings Aug 4, 2026 · consensus $-0.48 EPS
Last earnings +3.4% on 2026-05-12
$3.97
▲ +7.88%$3.97▲ +187.68%
over 1Y
L $1.16EODHDH $6.61
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+7.9%
1W+9.7%
1M+0.3%
3M+55.7%
YTD+189.8%
1Y+187.7%
Sell
Conviction
Horizon
Medium (3–12mo)
Street · 15 analysts
Buy
Conservative balance sheet (liabilities/equity 0.34x); but revenue fell -100.0% YoY.
Zentalis Pharmaceuticals, Inc. shows $0.00 in FY2025 revenue (-100.0% YoY), and -63.4% ROE.
Sources: SEC EDGAR (CIK 0001725160, latest 10-Q filed 2026-05-12) · EODHD · as of 6/25/2026, 2:18:01 AM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.